The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway

被引:214
作者
Sasaki, Y
Suzuki, M
Hidaka, H
机构
[1] Kitasato Univ, Sch Pharmaceut Sci, Dept Pharmacol, Minato Ku, Tokyo 1088641, Japan
[2] Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan
[3] D Western Therapeut Inst, Showa Ku, Nagoya, Aichi 4660825, Japan
关键词
Rho-kinase; LPA; synthetic inhibitors; H-1152; MARCKS;
D O I
10.1016/S0163-7258(02)00191-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have developed several kinds of protein kinase inhibitors, which are classified as isoquinolinesulfonamides and characterized as ATP competitive inhibitors of Ser/Thr protein kinases. These include H9, H89, KN62, and 1-(5-isoquinolinesulfonyl)-homopiperazine (HA-1077) against protein kinase C (PKC), protein kinase A, Ca2+/calmodulin-dependent protein kinase II, and Rho-kinase, respectively, and they have been used widely to confirm the involvement of the target protein kinase in biological or physiological reaction(s). In some cases, inhibitors have predicted the involvement of the target protein kinase in cell or tissue before its precise mechanism or its effector was defined. On a clinical level, we developed the Rho-kinase inhibitor HA-1077 as an anti-spastic that effectively suppresses the spasm of cerebral arteries after subarachnoid hemorrhage. We have improved HA-1077 to obtain (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine (H-1152P), which is a more selective inhibitor of Rho-kinase, with a K-i value of 1.6 nM for Rho-kinase, 630 nM for protein kinase A, and 9270 nM for PKC. This inhibitor suppressed the phosphorylation of myristoylated alanine-rich C-kinase substance (MARCKS) in neuronal cells stimulated with lysophosphatidic acid, whose phosphorylation site was confirmed to be the Ser159 residue, using a phosphorylation site-specific antibody. In contrast, phorbol 12-myristate 13-acetate-induced phosphorylation of MARCKS was scarcely inhibited by H-1152P. Furthermore, lysophophatidic acid-stimulated phosphorylation in neuronal cells was characterized as a C3 toxin-sensitive event. Our results show that the Rho-kinase inhibitor targets a protein with a well-known function, MARCKS in neuronal cells. Although MARCKS is widely recognized as a substrate of PKC, our results raise the possibility that MARCKS is a target protein of Rho-kinase in neuronal cells. In this review, we address the possible role of Rho-kinase in neuronal functions, using the Rho-kinase specific inhibitor H-1152P. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:225 / 232
页数:8
相关论文
共 40 条
[1]   A ROLE FOR MARCKS, THE ALPHA-ISOZYME OF PROTEIN-KINASE-C AND MYOSIN-I IN ZYMOSAN PHAGOCYTOSIS BY MACROPHAGES [J].
ALLEN, LAH ;
ADEREM, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (03) :829-840
[2]  
ASANO T, 1987, J PHARMACOL EXP THER, V241, P1033
[3]   A critical role for a Rho-associated kinase, p160ROCK, in determining axon outgrowth in mammalian CNS neurons [J].
Bito, H ;
Furuyashiki, T ;
Ishihara, H ;
Shibasaki, Y ;
Ohashi, K ;
Mizuno, K ;
Maekawa, M ;
Ishizaki, T ;
Narumiya, S .
NEURON, 2000, 26 (02) :431-441
[4]   Is pharmacological neuroprotection dependent on reduced glutamate release? [J].
Calabresi, P ;
Picconi, B ;
Saulle, E ;
Centonze, D ;
Hainsworth, AH ;
Bernardi, G .
STROKE, 2000, 31 (03) :766-772
[5]  
CHIJIWA T, 1989, J BIOL CHEM, V264, P4924
[6]   PHOSPHORYLATION OF SYNAPSIN-I AND MARCKS IN NERVE-TERMINALS IS MEDIATED BY CA2+ ENTRY VIA AN AGA-GI SENSITIVE CA2+ CHANNEL WHICH IS COUPLED TO GLUTAMATE EXOCYTOSIS [J].
COFFEY, ET ;
SIHRA, TS ;
NICHOLLS, DG ;
POCOCK, JM .
FEBS LETTERS, 1994, 353 (03) :264-268
[7]  
DEKKER LV, 1991, PROG BRAIN RES, V89, P209
[8]   Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: Its specific localization in smooth muscle [J].
Eto, M ;
Senba, S ;
Morita, F ;
Yazawa, M .
FEBS LETTERS, 1997, 410 (2-3) :356-360
[9]   Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells [J].
Fukata, Y ;
Amano, M ;
Kaibuchi, K .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (01) :32-39
[10]  
Goodall AR, 1997, J NEUROCHEM, V68, P392